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Conclusion: In TTR amyloidosis, NTproBNP and troponin T are associ-
ated with LV impairment measured by echocardiography suggesting that
NTproBNP could be useful in FAP carriers to start echocardiographic follow-
up whereas troponin would identify patients with severe cardiac disease.
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Background: Transthyretin familial amyloid polyneuropathy (TTR-FAP)
is an autosomal dominant disease characterized by extracellular amyloid
deposition in the nerves and heart. Orthotopic liver transplant (OLT) is recom-
mended to remove the source of mutated TTR and stop amyloid deposition.
However, progressive cardiomyopathy due to continuing amyloidosis has been
described following OLT in patients with non-V30M mutations. Tafamidis
prevents dissociation of TTR into monomers and formation of amyloid.
Objectives: To evaluate cardiac safety and tolerability of tafamidis in
patients with non-V30M TTR-FAP.
Methods: Patients (N=21) with TTR-FAP due to non-V30M TTR muta-
tions and no OLT history were studied in a phase 2 open-label trial. Cardiac
assessments included ECG, 24-hour Holter monitoring, echocardiogram,
and cardiac biomarkers (troponin I and NT-pro-BNP) at baseline and 6 and
12 months.
Results: Of the 21 patients enrolled, mean (SD) age, LVEF, troponin I,
and NT-pro-BNP at baseline were 63.1 (9.86) years, 60.3 (9.96)%,
0.023(0.04) ng/mL, and 1248.9 (1529.4) pg/mL, respectively. Nine patients
had a history of cardiac events. Six of these 9 experienced peripheral edema
or dyspnea related to heart failure while on treatment, and 3 patients were hos-
pitalized for other cardiovascular events (AV block, coronary stenosis, TIA).
Eighteen patients completed the study, with no significant changes in troponin
I, LVEF, or cardiac remodeling. NT-pro-BNP, while elevated at baseline,
remained stable with no clinically relevant changes. The pattern of Holter
monitoring abnormalities was similar at baseline and while on treatment (eg,
atrial tachycardia, 52.4% [11/21] vs 44.4% [4/9]). The percentage of patients
with normal heart rate variability (HRV) increased from 21% (4/19) at base-
line to 42% (8/19) at month 12.
Discussion: This study showed no deleterious effects of tafamidis on car-
diac function among a cohort of treated TTR-FAP patients. The number of
patients with normal HRV improved.
Conclusion: Tafamidis was safe and well tolerated in patients with non-
V30M TTR-FAP.
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Pupose: Diastolic Left ventricular (LV) dysfunction is a common finding
in sickle cell disease. Furthermore, left atrial (LA) size usually reflects left
ventricular filling pressures.
The aim of our study was to determine if LA size is an expression of left
ventricular filling pressures or reflects remodelling associated with anemia
and/or haemolysis in sickle cell disease.
Methods: We evaluated 127 patients with sickle cell disease in stable
condition (mean age 28,6±8,5 years, 83 women) and 38 age and sex-matched
healthy controls. LA size was measured with Simpson’s method in apical 4-
chamber view. LV filling pressures were assessed using ratio between pulsed
Doppler peak E velocity and peak Ea velocity obtained with tissue Doppler
imaging of the lateral annulus (E/Ea ratio). Clinical and biologic data were
collected from clinical records.
Results: Compared with the normal group, patients with sickle cell disease
had a LA volume and E/Ea ratio significatively increased (48,4±11,2 ml/m²
and 5,9±1,7 ; 30,5±7,6 ml/m² and 4,5±1, respectively, p<0.0001).
In multivariate analysis, LA enlargement in patients is only influenced by
age and haematological parameters (haemoglobin and reticulocyte levels).
No correlation was found between LA volume and E/Ea ratio (figure). 
Conclusion: Subjects with sickle cell disease have LA enlargement. However,
in this population, LA dilatation is not an index of left ventricular filling pressures.
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Background: Several arrhythmias were reported in myotonic dystrophy
(MD). The most frequent would be conduction disturbances and ventricular
arrhythmias. The purpose of the study was to evaluate the prevalence of atrial
flutter and fibrillation (AF) in MD and the consequences.
Methods: 157 patients, 80 men and 77 women, aged from 16 to 70 years,
mean age 41±14 years, at the inclusion, were consecutively recruited for a
type 1 MD. Patients were asymptomatic at the inclusion, except 4. Patients
were followed during 4.5±3.5 years. ECG, left ventricular ejection fraction
(LVEF) determination at echocardiography, Holter monitoring, signal-aver-
aged ECG were obtained and repeated.
Results: 24 patients presented sustained (> 1 hour) AF or atrial flutter
(n=8). The prevalence was 15%. Among these patients 2 presented a 1/1 atrial
flutter associated with syncope. In one of them, 16 years old, cardiac defibril-
lator was implanted for a diagnosis of ventricular tachycardia, but the real diag-
nostis was made after inappropriate shocks. Atrial flutter ablation was performed
in 4 patients but 3 of them developed AF. During follow-up, 21 patients died
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(15%) during the follow-up generally from cardiac and respiratory failure. 7 of
them had AF (29%) and 14 had no AF (10.5%) (p< 0.01). Univariate analysis
indicated that age greater than 40 years (death: 51±14 vs 40±14 in alive
patients), ECG, occurrence of sustained AF or flutter and LVEF less than 45%
were significant predictive factors of death. At multivariate analysis AF at ECG
(relative risk RR 6.72) was independent predictor of death.
Conclusions: Atrial flutter and atrial fibrillation are frequent in MD and
are associated with increasing mortality. Atrial flutter may present as a 1/1
atrial flutter (25%) with a poor tolerance and a risk of misdiagnostis.
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Introduction: Inherited cardiomyopathies and arrhythmias are autosomal
dominant diseases with an important genetic heterogeneity. Their overall pre-
valence, associated with the risk of sudden death, stress the need for high
throughput and sensitive genetic diagnosis in order to improve genetic
counseling and medical management. We evaluated the strength of Next Gene-
ration Sequencing (NGS) technologies to fulfill these criteria through simul-
taneous sequencing of the major known causative genes described as
responsible for these phenotypes.
Methods: We designed a custom target capture system (Agilent) of
64 genes followed by high-throughput sequencing on HiSeq2000 (Illumina).
Ten DNAs with mutations (in MYH7, MYBPC3, LMNA, FHL1, SCN5A,
KCNH2, KCNQ1, DSG2, DSP and PKP2 genes) were included as control.
Validation was done by evaluating capture efficiency, coverage deep,
sequencing sensitivity and reproducibility.
Results: More than 90% of targeted sequences were fully covered (> 50X).
After variants filtering, each DNA sample presented ~20 variations. Variants
were classified according to multiple criteria such as allelic frequency, mutation
type and functional effects. All 10 control mutations were identified. However
2 to 4 additional potential pathogenic variants were found in each individual.
Conclusion: NGS based diagnostic is reliable in cardiac disorders. This
technique should allow a sensitive, comprehensive, cost-effective and rapid
molecular diagnosis of patients. However, our results underlined the com-
plexity of the genetic profile of patients that should be taken into account into
clinical practice.
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Background: Although congestive heart failure (CHF) represents the most
common cause of death in native valve infective endocarditis (IE), recent data
on the outcome of IE complicated by CHF are lacking.
Objective: We aimed to analyse the characteristics and prognosis of
patients with left-sided native valve IE complicated by CHF and to evaluate
the impact of early surgery on 1 year outcome.
Methods and results: Two hundred and twenty consecutive patients with
definite left-sided native valve IE according to the Duke criteria were included
in this analysis. When compared with patients without CHF (n=144), new
heart murmur, high comorbidity index, aortic valve IE, and severe valve
regurgitation were more frequently observed in CHF patients (n=76, 34.5%).
Aortic valve IE, elderly patients were more frequent in CHF patients. Conges-
tive heart failure was independently predictive of in-hospital [OR 3.8 (1.7-
9.0); P=0.0013] and 1 year mortality [HR 1.8 (1.1-3.0); P=0.007]. Early sur-
gery was performed in 63% of CHF patients with a peri-operative mortality of
15%. In the CHF group, comorbidity index, anemia, uncontrolled infection,
and major neurological events were multivariate predictors of 1 year mortality.
Early surgery was independently associated with improved 1 year survival
[HR 0.45 (0.22-0.93); P=0.03].
Conclusion: Native valve IE complicated by CHF is more frequent in
aortic IE and is associated with severe regurgitation. Congestive heart failure
is an independent predictor of in-hospital and 1 year mortality. In CHF
patients, early surgery is independently associated with reduced mortality and
should be widely considered to improve outcome.
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Background: Emery-Dreifuss muscular dystrophy (EDMD) is an heredi-
tary syndrome related to mutations in lamin A/C gene (LMNA) and is charac-
terised by severe dilated cardiomyopathy, mostly slight peripheral muscular
dystrophy, supra-ventricular arrhythmia and atrio-ventricular (AV) block.
Transplantation for EDMD is rarely reported in the ISHLT registry. We aim
to study outcomes after heart transplantation (HTx) for end-stage heart failure
in twelve EDMD patients.
Methods: 12 cases of HTx performed for EDMD confirmed by genetic
analysis in a single institution between 1997 and 2011 were compared to
12 patients age, sex and year of transplantation matched. Survival curves were
analysed by Kaplan-Meier method.
Results: Before transplantation, EDMD patients had similar age (56 vs 57
yo, p=0,81), sex ratio (42% male), pre-transplantation NYHA functional class
III (p=0,207), left ventricular ejection fraction (LVEF=33% vs 32%, p=0,89),
higher rate of supra-ventricular arrythmia (100% vs 45%, p=0,002) and AV
block (58% vs 12.5%, p=0,042) compared to non-EDMD. After HTx, NYHA
functional class was similar (I, p=1,00), LVEF (72+/-5,91% vs 69+/-11,3%,
p=0,49), rejection rate (19+/-3,8% vs 40+/-8,2% by year, p=0,45), infection
rate (14% vs 6% by year, p=0,087), renal function (eGFR=89+/-49 vs 66+/-
37 ml/min, p=0,22) were similar after HTx in EDMD and non-EDMD group.
Survival rate at 1 year, 2 years, 5 years were not significantly different
(respectively 91.6%, 90.9%, 81.5% versus 100%, 100%, 100% p=0,146). 42%
EDMD patients had slight muscular dysfunction, compatible with good
quality of life.
Conclusion: Despite reluctance for heart transplantation in end-stage HF
patients with EDMD, long term outcomes are similar to non EDMD patients
at 1,2 and 5-year follow-up in our institution.
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Objective: to study left ventricular function in normotensive and low risk
diabetic patients.
